Evidence from randomised trials supports the use of GnRH analogues or danazol prior to endometrial resection and ablation in the early proliferative phase of the cycle.
This is mainly in terms of their effect on the intrauterine operating environment, making surgery technically easier.
There is generally no difference in complication rate but fluid deficit, intraoperative blood loss and operating times tend to be less, and short-term amenorrhoea rates may be higher. The benefit of these agents in the longer term is uncertain.